Susquehanna International Group’s Quince Therapeutics QNCX Stock Holding History

Susquehanna International Group’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1K	Buy	+55	New	+$11K	﹤0.01%	13028
2022 Q4	–	Sell	-323	Closed	-$86K	–	13436
2022 Q3	$86K	Sell	323 -104	-24%	-$39.6K	﹤0.01%	11818
2022 Q2	$190K	Sell	427 -717	-63%	-$507K	﹤0.01%	10710
2022 Q1	$1.42M	Sell	1,144 -836	-42%	-$1.14M	﹤0.01%	6284
2021 Q4	$5M	Sell	1,980 -130	-6%	-$793K	﹤0.01%	3738
2021 Q3	$38.7M	Buy	2,110 +1,196	+131%	+$19M	0.01%	1351
2021 Q2	$9.68M	Sell	914 -123	-12%	-$1.03M	﹤0.01%	2967
2021 Q1	$7.47M	Buy	1,037 +271	+35%	+$1.95M	﹤0.01%	3247
2020 Q4	$4.25M	Buy	766 +736	+2,453%	+$6.52M	﹤0.01%	3690
2020 Q3	$295K	Buy	+30	New	+$273K	﹤0.01%	8740

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna International Group's QNCX Position: Q1 2026 in Review

Susquehanna International Group reduced its Quince Therapeutics (QNCX) stake by 50% in Q1 2026, selling an estimated $173K and leaving 863 shares worth $17.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12876.

Susquehanna International Group first reported a position in QNCX in Q1 2021 and has held it in 17 quarters since. The position peaked at $6.12M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Susquehanna International Group held 863 shares of Quince Therapeutics worth $17.5K as of Q1 2026.
Susquehanna International Group sold 862 Quince Therapeutics shares in Q1 2026, an estimated $173K.
Quince Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12876 holding.
Susquehanna International Group first reported a position in Quince Therapeutics in Q1 2021 and has held it in 17 quarters since.
Susquehanna International Group's Quince Therapeutics position peaked at $6.12M in Q4 2021.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.